These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18408580)

  • 1. Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
    Cantarovich M; Ross H; Arizón JM; Gómez MA; Straatman L; Orús J; Alonso-Pulpón L; Molina BD; Wang S; Lage E; Crespo MG; Manito N; Howlett J; Haddad H;
    Transplantation; 2008 Apr; 85(7):992-9. PubMed ID: 18408580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients.
    Cibrik D; Meier-Kriesche HU; Bresnahan B; Wu YM; Klintmalm G; Kew CE; Kuo PC; Whelchel J; Cohen D; Baliga P; Akalin E; Benedetti E; Wright F; Lieberman B; Ulbricht B; Jensik S;
    Clin Transplant; 2007; 21(2):192-201. PubMed ID: 17425744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In response to: Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
    Knight SR; Morris PJ
    Transplantation; 2008 Sep; 86(6):885; author reply 886. PubMed ID: 18813115
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
    Internation Neoral Renal Transplantation Study Group
    Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
    Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
    Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients.
    Kung SC; Parikh M; Fyfe B; Xiao SG; Sierka D; Heifets M; Moritz M; Anil Kumar MS
    Transplant Proc; 2004 Mar; 36(2 Suppl):475S-477S. PubMed ID: 15041391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
    Levy G; Villamil F; Samuel D; Sanjuan F; Grazi GL; Wu Y; Marotta P; Boillot O; Muehlbacher F; Klintmalm G;
    Transplantation; 2004 Jun; 77(11):1632-8. PubMed ID: 15201658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction.
    Cantarovich M; Giannetti N; Cecere R
    Clin Transplant; 2003 Apr; 17(2):144-50. PubMed ID: 12709082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.
    Cantarovich M; Barkun J; Giannetti N; Cecere R; Besner JG; Tchervenkov J
    Transplant Proc; 2004 Mar; 36(2 Suppl):442S-447S. PubMed ID: 15041383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction.
    Delgado DH; Miriuka SG; Cusimano RJ; Feindel C; Rao V; Ross HJ
    J Heart Lung Transplant; 2005 Feb; 24(2):166-9. PubMed ID: 15701432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients.
    Vincenti F; Mendez R; Curtis J; Light J; Pearson T; Wu YM; Katz SM; Akalin E; Esterl R; Gugliuzza K; Shihab F; Jordan S; Jonsson J; Molmenti E; Barbeito R
    Transplantation; 2005 Oct; 80(7):910-6. PubMed ID: 16249738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.